Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...

Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems ...

Biovac has secured a $108.3 million financing package that will allow the South African pharma company to build the continent ...

In a blow to Bayer, a U.S. federal judge in Manhattan has said he will not block Johnson & Johnson’s survival claims on a key ...

Theramex has opted out of the U.K.’s self-regulatory program for pharma ma | Theramex has opted out of the U.K.’s ...

Genentech has launched the “Life Doesn’t Wait” campaign to mark World Hemophilia Day, dialing up its focus on patient stories ...